Five years on, Morgan Stanley PE to exit cardiac stent maker SMT

Existing investor Samara Capital and the promoter, Dhirajlal Kotadia and his family, are also likely to sell an about 15-20% stake between them. The potential deal is likely to value SMT at ₹3,500-4,000 crore and the process will be launched by the end of April, said the people. In 2018, Morgan Stanley acquired its 17% stake in SMT with an investment of ₹160 crore. Samara Capital holds a 32% stake, while Kotak Pre IPO Opportunities Fund owns 6% and the promoters hold the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ejThDyF
via IFTTT